Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer
New England Journal of Medicine2023Vol. 388(17), pp. 1547–1558
Citations Over TimeTop 1% of 2023 papers
Freddie C. Hamdy, Jenny Donovan, J. Athene Lane, Chris Metcalfe, Michael Davis, Emma L. Turner, Richard M. Martin, Grace Young, Eleanor Walsh, Richard J. Bryant, Prasad Bollina, Andrew Doble, Alan Doherty, David Gillatt, Vincent J. Gnanapragasam, Owen Hughes, Roger Kockelbergh, Howard Kynaston, Alan Paul, Edgar Páez, Philip Powell, Derek J. Rosario, Edward Rowe, Malcolm D. Mason, James W.F. Catto, T. J. Peters, Jon Oxley, Naomi Williams, John Staffurth, David E. Neal
Abstract
After 15 years of follow-up, prostate cancer-specific mortality was low regardless of the treatment assigned. Thus, the choice of therapy involves weighing trade-offs between benefits and harms associated with treatments for localized prostate cancer. (Funded by the National Institute for Health and Care Research; ProtecT Current Controlled Trials number, ISRCTN20141297; ClinicalTrials.gov number, NCT02044172.).
Related Papers
- → Identification of a 5-gene signature panel for the prediction of prostate cancer progression(2024)2 cited
- [ASC-J9 for castration-resistant prostate cancer].(2014)
- STUDY ON THE EFFECTS OF RADIOTHERAPY ON T-CELL SUBGROUPS OF THE MALIGNANT TUMOR PATIENTS(2000)
- Androgen Receptor Antagonists for the Treatment of Prostate Cancer(2012)